GYRE
Gyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.86
+6.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 119.4M | 116.6M | 105.8M | 113.5M | 102.3M |
| Cost of Revenue | 6.8M | 5.4M | 3.9M | 4.6M | 4.8M |
| Gross Profit | 112.6M | 111.2M | 101.9M | 108.8M | 97.5M |
| Operating Expenses | |||||
| R&D Expense | 33.1M | 13.7M | 12.0M | 13.8M | 16.7M |
| SG&A Expense | 93.1M | 86.0M | 73.6M | 75.8M | 71.6M |
| General & Admin Expense | 26.1M | 20.8M | 16.1M | 14.7M | 17.4M |
| Selling & Marketing Expense | 67.0M | 65.2M | 57.5M | 61.2M | 54.2M |
| Other Expenses | 3.1M | — | 66.0K | 86.4M | — |
| Total Operating Expenses | 129.2M | 99.7M | 85.7M | 176.0M | 88.3M |
| Cost and Expenses | 136.1M | 105.1M | 89.6M | 180.7M | 93.1M |
| Operating Income (EBIT) | (16.7M) | 11.5M | 16.2M | (67.2M) | 9.2M |
| Non-Operating | |||||
| Interest Income | 1.4M | 1.7M | 1.5M | 1.0M | 726.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 1.4M | 1.7M | 1.5M | 1.0M | 726.0K |
| Other Non-Op Income/Expense | 565.0K | 2.9M | 7.0M | (9.7M) | 209.0K |
| Non-Operating Income (excl Interest) | (565.0K) | (2.9M) | — | (86.4M) | (209.0K) |
| EBT (Pre-Tax Income) | (16.1M) | 14.4M | 23.2M | (77.0M) | 9.4M |
| Income Tax Expense | 2.2M | 4.6M | 5.3M | 8.5M | 5.1M |
| Bottom Line | |||||
| Net Income | (17.3M) | 5.0M | 12.1M | (92.9M) | 2.3M |
| Earnings from Cont. Ops | (18.3M) | 9.9M | 17.9M | (85.5M) | 4.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (18.4M) | 5.0M | 12.1M | (92.9M) | 2.3M |
| Per Share | |||||
| Basic EPS | ($0.20) | $0.06 | $0.14 | ($1.41) | $0.03 |
| Diluted EPS | ($0.20) | $0.02 | $0.05 | ($1.41) | $0.03 |
| Revenue Per Share | $1.19 | $1.30 | $1.24 | $1.72 | $1.35 |
| Shares | |||||
| Basic Shares Outstanding | 100.6M | 89.3M | 85.1M | 65.8M | 75.7M |
| Diluted Shares Outstanding | 100.6M | 103.2M | 102.3M | 65.8M | 75.7M |
| Profitability Metrics | |||||
| EBITDA | (14.0M) | 17.0M | 17.8M | 20.3M | 10.5M |
| D&A | 2.1M | 2.5M | 1.6M | 1.1M | 1.1M |
| EBIT | (16.1M) | 14.4M | 16.2M | 19.2M | 9.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026